Syndax Pharmaceuticals Inc. (SNDX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on cancer therapies. The company operates as a single segment and currently commercializes two FDA-approved products: Revuforj (revumenib) for acute leukemia and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease (cGVHD), the latter co-commercialized with Incyte Corporation.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Total Revenue | $72.8 million | $137.7 million | $57.8 million |
| Product Revenue (Revuforj) | $54.7 million | $103.6 million | $48.6 million |
| Collaboration Revenue (Niktimvo) | $18.1 million | $34.0 million | $9.1 million |
| Net Loss | $(49.4) million | $(92.0) million | $(156.7) million |
| Loss Per Share (Diluted) | $(0.55) | $(1.04) | $(1.82) |
| Cash & Investments | $575.1 million (as of June 30, 2026) | ||
| Debt Obligations | $244.1 million (Convertible Notes) + $344.0 million (Royalty Liability) | ||
| Operating Cash Flow | $(80.6) million used (YTD 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 138% year-over-year (YTD), driven by a 113% increase in product revenue from Revuforj and a 274% increase in collaboration revenue from Niktimvo.
- Improved Loss Profile: Net loss narrowed significantly to $92.0 million for the six months ended June 30, 2026, compared to $156.7 million in the prior year period.
- Capital Raise: In June 2026, the company issued $250.0 million in 2.25% Convertible Senior Notes due 2031, resulting in a net cash inflow of approximately $243.8 million after issuance costs.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased by $5.7 million YTD compared to 2025, primarily due to lower launch costs and reduced headcount.
- Interest Expense: Royalty interest expense increased to $24.0 million (YTD 2026) from $15.9 million (YTD 2025) due to the Royalty Pharma agreement, and new convertible note interest expense of $0.6 million was recognized.
Outlook, Risks, and Management Commentary
- Product Pipeline: Management highlighted strong prescription growth for Revuforj (approx. 1,500 prescriptions in Q2 2026, up 121% YoY). New pipeline assets SNDX-4321 (EGFR inhibitor) and SNDX-62122 (next-gen menin inhibitor) were announced in July 2026.
- Clinical Milestones: The company expects topline data for axatilimab in newly diagnosed cGVHD and IPF in late 2026. Several Phase 3 trials for Revuforj (EVOLVE-2, REVEAL-ND) are ongoing.
- Liquidity: Management believes current cash, investments ($575.1 million), and expected product revenues are sufficient to fund operations for the foreseeable future.
- Risks: Key risks include the ability to service debt obligations (convertible notes and royalty financing), the uncertainty of clinical trial outcomes, and potential dilution from the conversion of notes. The company maintains a full valuation allowance on deferred tax assets.
Investor Verification Checklist
- Debt Service Capacity: Verify the company's ability to meet semi-annual interest payments on the new $250M convertible notes and quarterly royalty payments to Royalty Pharma.
- Revenue Sustainability: Confirm the trajectory of Revuforj prescription growth and the impact of payer mix/reimbursement on net product revenue.
- Clinical Data Readouts: Monitor upcoming data releases for Revuforj in frontline AML settings and axatilimab in IPF and newly diagnosed cGVHD.
- Convertible Note Terms: Review the conversion price ($24.76) and conditions for the 2031 Notes to assess potential future dilution.
- Collaboration Terms: Understand the profit-sharing mechanics with Incyte regarding Niktimvo, as this drives a significant portion of current revenue.